context therapeutics is dedicated to discovering, acquiring, and developing novel compounds to treat hormone responsive cancers. our lead program is apristor (onapristone xr), an investigational drug for progesterone receptor positive (pr+) breast cancer. 

Context Therapeutics Inc. Common Stock

Sold all CNTX

This member connected a brokerage account and is sharing trades and portfolio performance with the community. 

Public Portfolio

Riley Wong

New position in CNTX

Sold 50% of CNTX

Abilash Satya

Bought 25% more CNTX

Rahul

Bought 60% more CNTX

Matt Markland

Bought 11% more CNTX

Bought 82% more CNTX

Chris J

Bought 59% more CNTX

John